Terrence Reding, MD
Sports Medicine · Oxnard, CANPI 1922150150
Payments from drug & device makers
Across 39 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$126
- Lilly USA, LLC$119
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$105
- Merck$83
- GSK$77
- Biohaven Pharmaceutical Holding Company Ltd.$30
- plus $183 from 9 others
What the payments were for
- Food & beverage$723100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 7 | $126 |
| Lilly USA, LLC | 6 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $105 |
| Merck | 4 | $83 |
| GSK | 4 | $77 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Vertex | 1 | $28 |
| Gilead | 1 | $27 |
| Pfizer | 1 | $25 |
| Organon | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Mannkind Corporation | 1 | $17 |
| Alkermes, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Verrica Pharmaceuticals Inc. | 1 | $13 |
How this compares
$723 in reported general payments places this provider in the 35th percentile of 662 sports medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 157 | $5,569 |
| Ventolin HfaAlbuterol Sulfate | 15 | $950 |
| Cephalexin | 110 | $628 |
| Doxycycline Hyclate | 108 | $588 |
| Ondansetron OdtOndansetron | 36 | $568 |
| Ketoconazole | 20 | $479 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 26 | $425 |
| Gabapentin | 70 | $353 |
| Fluticasone Propionate | 32 | $341 |
| Azithromycin | 134 | $330 |
| MoxifloxacinMoxifloxacin Hcl | 13 | $325 |
| Oseltamivir Phosphate | 13 | $259 |
| Ibuprofen | 56 | $220 |
| Amoxicillin | 73 | $187 |
| Prednisone | 83 | $185 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Oxnard
- Neal ElattracheLos Angeles$51M
- Nathaniel CohenLos Gatos$6.4M
- Thomas KnappSanta Monica$2.5M
- Seth ShermanStanford$1.8M
- Michael FreehillStanford$1.7M
- Deryk JonesSan Carlos$1.6M
- Allan MishraMenlo Park$1.5M
- Heinz Hoeneckela Jolla$1.4M
- Marc SafranPalo Alto$1.2M
- Stephan YacoubianBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.